Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

155
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
155
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

796
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
796
Phase II Reactions: Acetylation Reactions01:24

Phase II Reactions: Acetylation Reactions

188
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
188
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

618
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
618
Antidotes01:17

Antidotes

611
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
611
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

693
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
693

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual Clinics in Cardiology: Do They Provide Equivalent Care and Reduce Travel?

Journal of clinical medicine·2025
Same author

Acute Methaemoglobinaemia as an Overlooked Cause of Acute Dyspnoea in a Patient With Chronic Obstructive Pulmonary Disorder in the Emergency Department.

Cureus·2025
Same author

Nontraumatic right diaphragmatic hernia with malrotated left liver lobe incarceration: An unusual case report with literature review.

Radiology case reports·2025
Same author

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease.

Annals of medicine and surgery (2012)·2024
Same author

Anterior Cruciate Ligament Arthroscopic Ligamentoplasty Using the Four-Strand Hamstring Technique.

Cureus·2023
Same author

Incidence and Determinants of Complications of Percutaneous Kidney Biopsy in a Large Cohort of Native Kidney and Kidney Transplant Recipients.

Sultan Qaboos University medical journal·2022

Related Experiment Video

Updated: Jun 9, 2025

Screening Assay for Oxidative Stress in a Feline Astrocyte Cell Line, G355-5
09:53

Screening Assay for Oxidative Stress in a Feline Astrocyte Cell Line, G355-5

Published on: July 13, 2011

14.4K

N-acetylcysteine Clinical Applications.

Zoubaida Yahia1, Amer Yahia2, Tarek Abdelaziz3

  • 1General Practice, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, GBR.

Cureus
|October 25, 2024
PubMed
Summary
This summary is machine-generated.

N-acetylcysteine (NAC) shows promise as a safe and affordable adjunctive therapy for numerous chronic diseases beyond its established uses. Further research into NAC

Keywords:
adjunct therapycataractschronic diseasesendometriosisglaucomamale infertilityn-acetylcysteineneurodegenerative diseasespolycystic ovary syndromepsychiatric disorders

More Related Videos

Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

46.2K
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

7.4K

Related Experiment Videos

Last Updated: Jun 9, 2025

Screening Assay for Oxidative Stress in a Feline Astrocyte Cell Line, G355-5
09:53

Screening Assay for Oxidative Stress in a Feline Astrocyte Cell Line, G355-5

Published on: July 13, 2011

14.4K
Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

46.2K
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

7.4K

Area of Science:

  • Medical research
  • Pharmacology
  • Clinical applications

Background:

  • N-acetylcysteine (NAC) is recognized for treating acetaminophen overdose, cystic fibrosis, and COPD.
  • Emerging evidence suggests broader therapeutic benefits of NAC due to its safety and affordability.
  • Glutathione levels decline with aging, increasing interest in NAC's potential role.

Purpose of the Study:

  • To evaluate the therapeutic applications of N-acetylcysteine (NAC) as a treatment or adjunct therapy.
  • To explore NAC's potential benefits for a wide spectrum of medical conditions.
  • To review existing evidence on NAC's efficacy in various diseases.

Main Methods:

  • A comprehensive literature review was conducted using PubMed, books, and conference proceedings.
  • Clinically relevant data were analyzed using the American Family Physician Evidence-Based Medicine Toolkit.
  • An integrated review methodology was followed for data analysis.

Main Results:

  • NAC demonstrates potential as an adjunctive treatment for numerous chronic diseases.
  • Specific conditions where NAC may be beneficial include PCOS, endometriosis, infertility, neurodegenerative diseases, liver conditions, inflammatory bowel diseases, and psychiatric disorders.
  • Evidence for some conditions is less robust, necessitating further investigation.

Conclusions:

  • N-acetylcysteine (NAC) exhibits significant therapeutic potential as an adjunctive therapy for a broad range of chronic diseases.
  • NAC supplementation could play a crucial role in reducing morbidity and mortality in various conditions.
  • Further investigation is warranted to solidify NAC's role in diverse medical applications.